• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Association of cannabis use with opioid outcomes among opioid-dependent youth.

OBJECTIVE: Cannabis use is common among opioid-dependent patients, but studies of its association with treatment outcome are mixed. In this secondary analysis, the association of cannabis use with opioid treatment outcome is assessed. METHODS: In the main study, participants (n=152) aged 15-21 years were randomized to receive psychosocial treatments and either a 12-week course of buprenorphine-naloxone with a dose taper to zero in weeks 9-12, or a 2-week detoxification with buprenorphine-naloxone. Drug use was assessed by self-report and urine drug screen at baseline and during study weeks 1-12. The association between cannabis and opioid use at weeks 4, 8, and 12 was examined using logistic regression models. RESULTS: Participants reported a median of 3.0 days (range=0-30) cannabis use in the past month; half (50.3%; n=77) reported occasional use, one-third reported no use (33.1%; n=50), and one-sixth reported daily cannabis use (16.6%; n=25). Median lifetime cannabis use was 4.0 years (range=0-11) and median age of initiation of use was 15.0 years (range 9-21). Neither past cannabis use (age of initiation and use in the month prior to baseline) nor concurrent use was associated with level of opioid use. CONCLUSIONS: Overall, cannabis use had no association with opioid use over 12 weeks in this sample of opioid-dependent youth. While cannabis use remains potentially harmful, it was not a predictor of poor opioid treatment outcome.

Pubmed ID: 23528523


  • Hill KP
  • Bennett HE
  • Griffin ML
  • Connery HS
  • Fitzmaurice GM
  • Subramaniam G
  • Woody GE
  • Weiss RD


Drug and alcohol dependence

Publication Data

September 1, 2013

Associated Grants

  • Agency: NIDA NIH HHS, Id: CTN U10 DA15831
  • Agency: NIDA NIH HHS, Id: K24 DA022288
  • Agency: NIDA NIH HHS, Id: K24 DA022288
  • Agency: NIDA NIH HHS, Id: K99 DA029115
  • Agency: NIDA NIH HHS, Id: K99/R00 DA029115
  • Agency: NIDA NIH HHS, Id: R00 DA029115
  • Agency: NIDA NIH HHS, Id: U10 DA013043
  • Agency: NIDA NIH HHS, Id: U10 DA015831

Mesh Terms

  • Adult
  • Buprenorphine
  • Data Interpretation, Statistical
  • Female
  • Humans
  • Logistic Models
  • Male
  • Marijuana Abuse
  • Naloxone
  • Narcotic Antagonists
  • Narcotics
  • Opioid-Related Disorders
  • Substance Abuse Detection
  • Treatment Outcome
  • Young Adult